FERRING
Ferring Pharmaceuticals and CD Investments (CDI) announced today that they have signed an agreement granting Ferring exclusive European marketing rights to CDI’s VSL#3® . This agreement extends Ferring’s existing rights to market the product in the UK, Italy and Canada.
VSL#3® is a food supplement, containing 450 billion live bacteria in eight different strains per sachet, which colonizes the gut and benefits from a unique formulation. Research has confirmed that probiotic bacteria modulate mucosal and systemic immune activity and epithelial function(1) , with favorable impact on gut health.
“VSL#3® expands our existing gastroenterology portfolio and is a key part of our regional pharmabiotic strategy,” said Gilles Pluntz, Senior Vice President Europe-Canada, Ferring Pharmaceuticals. “This agreement complements our innovative research in the area of the human microbiome, and reflects Ferring’s commitment to enhancing the quality of life of patients with a broad range of bowel conditions.”
“We are delighted to expand our collaboration with Ferring, and build on the current success of VSL#3® in the UK, Italy and Canada,” said Luca Guarna, President of the Board of Directors of CD Investments. “With the company’s long heritage in gastroenterology and commitment to patients, Ferring will help make VSL#3® a successful brand across Europe and Canada.”
- Ends -
About VSL#3 ®
VSL#3® is a combination of live lactic acid bacteria that have been cultivated, freeze-dried and mixed in a very high concentration (hundreds of billions per gram). It contains eight different strains of bacteria which have been selected, cultivated in and mixed in proportions in order to optimize the functionality of the product. To learn more about VSL#3® please visit www.vsl3pharma.com .
About the Microbiome
To understand the role that probiotics may have in influencing health, it is important to have an appreciation of the roles of the normal intestinal microbiome. The human body is host to trillions of microbes, bacteria, virus and fungi. This vast and complex microbial community is known as the microbiota. Each of the different microorganisms in the microbiota has its own unique set of genes. The collective name for all of the genes in the microbiota is the microbiome. Rapidly evolving science has uncovered a central role of the microbiome in human health and disease.
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a private research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com .
About CD Investments (VSL Pharmaceuticals, Inc.)
CD Investments is a holding company with three subsidiaries worldwide, CD Investments for the European market, CD Pharma India for the Asia-Pacific market and VSL Pharmaceuticals for the North, Central and South America.
CD Investments is focused on the development of products based on the technological platform of probiotic bacteria (lactic acid bacteria and bifidobacteria) for use as food supplement/nutraceuticals in various physiological/pathological conditions. The company has a number of patents which cover many aspects of the therapeutic and nutraceutical use of probiotics and of enzymes derived from probiotic bacteria, in different pathophysiological conditions, both as dietetic preparations, and food supplements, or as pharmaceutical products. To learn more about CD Investment please visit www.vsl3pharma.com .
(1) Fedorak R., J Clin Gastroenterol - Volume 42, Supp. 3, Part 1, September 2008 S111
View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005512/en/
Contact:
Ferring Pharmaceuticals
Carine Julen
Tel. +41 58 301 01 78
carine.julen@ferring.com
or
CD
Investments
Davide Grasso
Tel. +39 06 54211033
d.grasso@vsl3pharma.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release
~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut
The Six Winning Projects of the 12th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open27.5.2025 16:58:00 CEST | Press release
The winners of the 2024 IBSA Foundation Fellowships Call come from two US, two Swedish, one Italian and one British universities.This year’s edition set a new record: 259 projects submitted from 45 countries.The awards ceremony was held today in Milan; during the event, the 2025 call for applications was officially opened. Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/ The Award Ceremony of the
Rigaku Completes New Building at Yamanashi Plant27.5.2025 16:00:00 CEST | Press release
Dramatic 2.7-fold increase in floor space to serve global demand Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527974928/en/ Exterior view of the New Building, Yamanashi Plant Doubling of production capacity: a strategic base to support Rigaku’s growth Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom